These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 15168086)

  • 21. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells.
    Hombach A; Schneider C; Sent D; Koch D; Willemsen RA; Diehl V; Kruis W; Bolhuis RL; Pohl C; Abken H
    Int J Cancer; 2000 Oct; 88(1):115-20. PubMed ID: 10962448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.
    Elia AR; Circosta P; Sangiolo D; Bonini C; Gammaitoni L; Mastaglio S; Genovese P; Geuna M; Avolio F; Inghirami G; Tarella C; Cignetti A
    Hum Gene Ther; 2015 Apr; 26(4):220-31. PubMed ID: 25758764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes.
    Lamers CH; Sleijfer S; Willemsen RA; Debets R; Kruit WH; Gratama JW; Stoter G
    J Biol Regul Homeost Agents; 2004; 18(2):134-40. PubMed ID: 15471217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric Antigen Receptor T Cell Therapy in Hematology.
    Ataca P; Arslan Ö
    Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
    Marcus A; Eshhar Z
    Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.
    Weijtens ME; Willemsen RA; van Krimpen BA; Bolhuis RL
    Int J Cancer; 1998 Jul; 77(2):181-7. PubMed ID: 9650549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A stable single-chain variable fragment expressing transfectoma demonstrates induction of idiotype-specific cytotoxic T-cells during early growth stages of a murine B-lymphoma.
    Laxmanan S; Stuart GW; Ghosh SK
    Cancer Immunol Immunother; 2001 Oct; 50(8):437-44. PubMed ID: 11726138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic engineering of T cell specificity for immunotherapy of cancer.
    Willemsen RA; Debets R; Chames P; Bolhuis RL
    Hum Immunol; 2003 Jan; 64(1):56-68. PubMed ID: 12507815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes.
    Lev A; Novak H; Segal D; Reiter Y
    J Immunol; 2002 Sep; 169(6):2988-96. PubMed ID: 12218113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression.
    Chmielewski M; Kopecky C; Hombach AA; Abken H
    Cancer Res; 2011 Sep; 71(17):5697-706. PubMed ID: 21742772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases].
    Vdovin AS; Bykova NA; Efimov GA
    Mol Biol (Mosk); 2017; 51(6):1008-1023. PubMed ID: 29271964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
    Daniyan AF; Brentjens RJ
    J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor.
    Gyobu H; Tsuji T; Suzuki Y; Ohkuri T; Chamoto K; Kuroki M; Miyoshi H; Kawarada Y; Katoh H; Takeshima T; Nishimura T
    Cancer Res; 2004 Feb; 64(4):1490-5. PubMed ID: 14973062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.